Creators of Cycloset®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info
https://www.prnewswire.com/news-releases/veroscience-continues-to-explore-clinical-benefits-of-circadian-neuroendocrine-resetting-therapy-with-six-papers-presented-at-2016-american-diabetes-association-scientific-sessions-june-10-14-300283267.html
http://professional.diabetes.org/meeting/scientific-sessions/76th-scientific-sessions
http://professional.diabetes.org/meeting/other/30th-annual-clinical-conference-diabetes
http://www.clevelandclinicmeded.com/live/courses/diabetesday/default.asp
https://medcitynews.com/2015/08/can-deconstructing-the-biological-clock-help-treat-diabetes-and-cancer/comment-page-1/
http://medcitynews.com/2015/08/can-deconstructing-the-biological-clock-help-treat-diabetes-and-cancer/
http://www.prnewswire.com/news-releases/two-peer-reviewed-studies-focusing-on-unique-therapeutic-impact-of-verosciences-cycloset-recently-published-in-journal-of-diabetes-research-300098977.html
http://www.prnewswire.com/news-releases/veroscience-continues-clinical-evaluation-of-bromocriptine-qr-cycloset-and-neurophysiological-investigations-of-brain-dopamine-regulation-of-metabolism-with-eight-papers-presented-at-the-2015-american-diabetes-association-confer-300095056.html
Cycloset is recommended for dual therapy for patients with entry HbA1c ≥ 7.5% SAN DIEGO & TIVERTON, R.I. –(BUSINESS WIRE)– Santarus, Inc. […]
